CytoDyn to Hold Webcast on April 6 to Provide a Full Update on Its Activities
CytoDyn (CYDY) announced an investment community webcast on April 6, 2021, hosted by its executive team, including CEO Nader Pourhassan and CMO Scott Kelly.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CytoDyn (CYDY) announced an investment community webcast on April 6, 2021, hosted by its executive team, including CEO Nader Pourhassan and CMO Scott Kelly. The update will cover the company's recent initiatives related to COVID-19, as well as ongoing trials for NASH and cancer treatments. The session will be approximately 60 minutes long, allowing for questions submitted by analysts and investors. Participants can access the webcast on CytoDyn's corporate website and a replay will be available for 30 days afterwards.
Positive
- Webcast scheduled for April 6, 2021, will provide updates on COVID-19 initiatives and clinical trials.
- Opportunity for investors to engage with management and submit questions.
Negative
- None.
Details
News Market Reaction – CYDY
The recorded move for CYDY in the trading session of this news was +18.15%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, Washington, April 01, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman and Chief Medical Officer, Christopher Recknor, M.D., Chief Operating Officer and Mahboob Rahman, M.D., Ph.D., Chief Scientific Officer, will host an investment community webcast on Tuesday, April 6, 2021.
Management will provide a full update to its stockholders on Company activities, including recent COVID-19 initiatives and information concerning its active trials in COVID-19, NASH and cancer.
Management will provide approximately 60 minutes to address questions submitted online by analysts and investors.
Date: Tuesday, April 6, 2021
Time: 1:00 pm PT / 4:00 pm ET
Dial-In: None.
Questions:
- Prior to the webcast, questions can be submitted online to CYDY_Team@cytodyn.com
- During the webcast, questions can be submitted through the webcast link below.
This is a “listen only” webcast, which can be accessed via CytoDyn’s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 30 days. Participants are encouraged to go to the website 15 minutes prior to the start of the webcast to register, download and install any necessary software. Please note the below website will not be operational until approximately 60 minutes prior to the start of the webcast, which can be accessed via the following link:
https://78449.themediaframe.com/dataconf/productusers/cydy/mediaframe/44397/indexl.html
The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until May 6, 2021.
CONTACTS
Investors:
Michael Mulholland
Office: 360.980.8524, ext. 102
mmulholland@cytodyn.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.